Phapros (PEHA) Q1 2026 Profit Rises, Driven by Sales Growth

JAKARTA, KOMPAS.com — The pharmaceutical issuer PT Phapros Tbk (PEHA) recorded an increase in net profit for the first quarter of 2026, driven by sales growth and cost efficiencies amid global pressures. This performance continues the positive trend throughout 2025, where the company successfully reversed its financial condition from losses to profits. “Various strategic measures have successfully maintained sustainable profitability,” said Acting President Director of PT Phapros Tbk Ida Rahmi Kurniasih, in a press statement on Friday (24/4/2026). “After successfully reversing the condition from losses in 2024 to profits in 2025, we continue to strive to maintain the company’s profitability,” she added. This performance was supported by a 10.17% increase in sales to Rp 221.09 billion from Rp 200.67 billion in the first quarter of 2025. Meanwhile, the cost of goods sold only rose by 5.04%, lower than the sales growth. This condition drove a 16.59% increase in gross profit to Rp 103.96 billion, compared to Rp 89.17 billion in the same period last year. On the other hand, operating expenses from January to March 2026 were also relatively controlled, with a 7.35% year-on-year increase. “In response to the geopolitical impacts causing rises in raw material prices and costs, we have already carried out risk mitigation with purchase contracts since the beginning of the year and continue to monitor developments to remain adaptive,” she said. “The aim is to secure sales, cost, and net profit targets until the end of the year in line with the RKAP,” she added.